B C Pestalozzi

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. doi request reprint CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
    Bernhard C Pestalozzi
    Department of Oncology, University Hospital, Zurich, Switzerland
    Lancet Oncol 14:244-8. 2013
  2. pmc Hemorrhage associated with hepatic artery pseudoaneurysms after regional chemotherapy with floxuridine: case report
    Panagiotis Samaras
    Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Int Semin Surg Oncol 5:17. 2008
  3. pmc Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Department of General and Abdominal Surgery, University Hospital of Mainz, Langenbeck Strasse 1, 55118 Mainz, Germany
    BMC Cancer 11:346. 2011
  4. doi request reprint Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
    Bernhard C Pestalozzi
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    J Clin Oncol 26:3006-14. 2008
  5. pmc Is an aggressive surgical approach worthwhile in biliary cancer?
    Nadja Ristagno
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    Int Semin Surg Oncol 4:26. 2007
  6. ncbi request reprint [Therapeutic advances in breast cancer]
    B C Pestalozzi
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich, Zurich
    Ther Umsch 63:255-61. 2006
  7. ncbi request reprint Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
    B C Pestalozzi
    Department of Oncology, University Hospital, Zurich, Switzerland
    Ann Oncol 17:935-44. 2006
  8. ncbi request reprint Non-Hodgkin's lymphoma in patients 80 years of age or older
    O Bairey
    Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Department of Internal Medicine A, Sapir Medical Center, Kfar Saba, Israel
    Ann Oncol 17:928-34. 2006
  9. pmc Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial
    B C Pestalozzi
    Department of Oncology, University Hospital, Zurich, Switzerland
    Ann Oncol 19:1837-41. 2008
  10. ncbi request reprint [New antibodies in cancer treatment]
    B C Pestalozzi
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich
    Praxis (Bern 1994) 93:1589-92. 2004

Detail Information

Publications32

  1. doi request reprint CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
    Bernhard C Pestalozzi
    Department of Oncology, University Hospital, Zurich, Switzerland
    Lancet Oncol 14:244-8. 2013
    ..We assessed the frequency and course of CNS relapses, either as first event or at any time, using data from the HERA trial...
  2. pmc Hemorrhage associated with hepatic artery pseudoaneurysms after regional chemotherapy with floxuridine: case report
    Panagiotis Samaras
    Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Int Semin Surg Oncol 5:17. 2008
    ..Pseudoaneurysms usually occur after mechanical damage of the vessel wall, but the chemical toxicity of floxuridine may add to the development of vascular impairment...
  3. pmc Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Department of General and Abdominal Surgery, University Hospital of Mainz, Langenbeck Strasse 1, 55118 Mainz, Germany
    BMC Cancer 11:346. 2011
    ..Moreover, neoadjuvant chemotherapy improves the nutritional status of patients with pancreatic cancer. This multicenter phase III trial (NEOPAC) has been designed to explore the efficacy of neoadjuvant chemotherapy...
  4. doi request reprint Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
    Bernhard C Pestalozzi
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    J Clin Oncol 26:3006-14. 2008
    ..To determine how patients with infiltrating lobular carcinoma (ILC) differ from patients with the more common infiltrating ductal carcinoma (IDC) with regard to patient and tumor factors, local treatment, and patterns of recurrence...
  5. pmc Is an aggressive surgical approach worthwhile in biliary cancer?
    Nadja Ristagno
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    Int Semin Surg Oncol 4:26. 2007
    ..Recently, much more aggressive surgical approaches have been employed. Therefore, we have investigated outcome of biliary cancer before and after establishment of an aggressive surgical approach...
  6. ncbi request reprint [Therapeutic advances in breast cancer]
    B C Pestalozzi
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich, Zurich
    Ther Umsch 63:255-61. 2006
    ..By contrast, in the adjuvant setting combination drug therapy is the standard. New methods of tissue analysis including expression patterns of mRNA and proteins are promising research strategies to further advance the field...
  7. ncbi request reprint Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
    B C Pestalozzi
    Department of Oncology, University Hospital, Zurich, Switzerland
    Ann Oncol 17:935-44. 2006
    ..We sought to determine whether a high-risk group could be defined among patients with operable breast cancer in whom a search of occult central nervous system (CNS) metastases was justified...
  8. ncbi request reprint Non-Hodgkin's lymphoma in patients 80 years of age or older
    O Bairey
    Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Department of Internal Medicine A, Sapir Medical Center, Kfar Saba, Israel
    Ann Oncol 17:928-34. 2006
    ..Very elderly patients (> or =80 years old) with non-Hodgkin's lymphoma (NHL) frequently have co-morbid conditions and are generally excluded from clinical trials or even from treatment. The optimal treatment of these patients is unknown...
  9. pmc Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial
    B C Pestalozzi
    Department of Oncology, University Hospital, Zurich, Switzerland
    Ann Oncol 19:1837-41. 2008
    ..Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes...
  10. ncbi request reprint [New antibodies in cancer treatment]
    B C Pestalozzi
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich
    Praxis (Bern 1994) 93:1589-92. 2004
    ..They are used today routinely in the treatment of malignant lymphoma and breast cancer, respectively. These antibodies are usually used in combination with conventional cytostatic anticancer drugs...
  11. doi request reprint Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
    Panagiotis Samaras
    Department of Oncology and Surgery, University Hospital Zurich, Zurich, Switzerland
    Ann Surg Oncol 18:1924-31. 2011
    ..An outcome assessment was performed of patients with unresectable colorectal liver metastases (CRLM) treated in second or third line with floxuridine (FUDR)-based hepatic artery infusion (HAI)...
  12. ncbi request reprint [Systemic therapy for colorectal cancer]
    B C Pestalozzi
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich, Schweiz
    Chirurg 76:570-2, 574. 2005
    ..Monoclonal antibodies like bevacizumab and cetuximab have been integrated into modern treatment regimens. Based on randomized clinical trials we can formulate rational treatment strategies as outlined in this article...
  13. ncbi request reprint [New drugs for colorectal cancer]
    B C Pestalozzi
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich
    Praxis (Bern 1994) 93:1455-9. 2004
    ..Very new and exciting are reports with the monoclonal antibody bevacizumab in combination with chemotherapy. Bevacizumab blocks angiogenesis. So far it is available only in the USA...
  14. ncbi request reprint [Molecular targeted therapy]
    F Stenner-Liewen
    Klinik und Poliklinik für Onkologie, Universitatsspital Zurich, Ramistrasse 100, 8091 Zurich, Schweiz
    Chirurg 77:1118-25. 2006
    ..This article gives an overview of the development of this fourth modality in cancer therapy, so-called targeted therapy...
  15. doi request reprint Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    J Nucl Med 49:1408-13. 2008
    ..Our objective was to evaluate the value of combined contrast-enhanced (18)F-FDG PET/CT in assessing the resectability of pancreatic cancer and to compare enhanced PET/CT with the performance of PET alone and unenhanced PET/CT...
  16. ncbi request reprint Potential use of humanized antibodies in the treatment of breast cancer
    Niklaus G Schaefer
    Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Raemistr, 100, CH 8091 Zurich, Switzerland
    Expert Rev Anticancer Ther 6:1065-74. 2006
    ..Here, an overview of humanized antibodies in human breast cancer is provided, with emphasis on the recent advances and future prospects in treating malignant breast cancer...
  17. doi request reprint Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation
    Konstantin J Dedes
    Department of Gynecology, University Hospital of Zurich, Frauenklinkstrasse, 8091 Zurich, Switzerland
    Eur J Cancer 45:1397-406. 2009
    ..Probabilistic sensitivity analysis showed that the willingness-to-pay threshold of 60,000euro was never reached. The addition of bevacizumab to paclitaxel in MBC patients is expensive given the clinical benefit in terms of QALYs gained...
  18. doi request reprint Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients
    Panagiotis Samaras
    Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Oncology 74:237-44. 2008
    ..We assessed longevity and complications of totally implantable venous access devices in oncology patients...
  19. ncbi request reprint Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis
    M Lesurtel
    Swiss HPB Hepato Pancreato Biliary Center, Department of Visceral and Transplant Surgery, University Hospital, Zurich, Switzerland
    Am J Transplant 6:2644-50. 2006
    ..There is insufficient evidence that TACE offers any benefit when used prior to OLT, neither for early nor for advanced HCC. Well-designed randomized controlled trials are needed to define the role of TACE in OLT patients...
  20. doi request reprint Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head
    Stefan Heinrich
    Department of Visceral and Transplantation Surgery, Institute of Surgical Pathology, Swiss Hepato Pancreato Biliary Center, Zurich, Switzerland
    J Clin Oncol 26:2526-31. 2008
    ..To test the safety of neoadjuvant chemotherapy for resectable pancreatic cancer...
  21. doi request reprint Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial
    Stefan Heinrich
    Swiss HPB Center, Department of Surgery and Institute of Surgical Pathology, Zurich, Switzerland
    Ann Surg 248:1014-22. 2008
    ..To evaluate the morbidity of pancreaticoduodenectomy after neoadjuvant chemotherapy for resectable pancreatic cancer and to assess its histologic and metabolic response...
  22. ncbi request reprint Critical evaluation of the different staging systems for hepatocellular carcinoma
    S Wildi
    Department of Visceral and Transplantation Surgery, University Hospital of Zurich, 8091 Zurich, Switzerland
    Br J Surg 91:400-8. 2004
    ....
  23. ncbi request reprint FDG-negative signet ring cell cancer of the stomach with FDG-positive skin metastases
    Ujval Bhure
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    Clin Nucl Med 32:226-8. 2007
  24. ncbi request reprint Peritoneal carcinoma in a male patient
    Monika Jermann
    Division of Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Oncology 64:468-72. 2003
    ..Our case confirms the existence of primary peritoneal carcinoma in males. In addition, it shows that this entity responds to the same chemotherapy as used for ovarian cancer and primary peritoneal carcinoma in females...
  25. doi request reprint Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas
    Marc Oliver Riener
    Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Histopathology 56:600-6. 2010
    ..To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer...
  26. ncbi request reprint Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Markus M Borner
    Institute of Medical Oncology, Inselspital, Switzerland
    J Clin Oncol 20:1759-66. 2002
    ..To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer...
  27. doi request reprint Hepatic arterial infusion: the beginning of the combination era
    Bernhard C Pestalozzi
    J Clin Oncol 26:2231-2; author reply 2232-3. 2008
  28. pmc Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness
    Stefan Heinrich
    Department of Visceral and Transplantation Surgery, University Hospital of Zurich, Switzerland
    Ann Surg 242:235-43. 2005
    ..We sought to determine the impact of positron emission tomography/computed tomography (PET/CT) on the management of presumed resectable pancreatic cancer and to assess the cost of this new staging procedure...
  29. doi request reprint Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
    Jurg Bernhard
    Swiss Group for Clinical Cancer Research Coordinating Center, Bern, Switzerland
    J Clin Oncol 26:3695-701. 2008
    ..To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer...
  30. ncbi request reprint Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial
    Catrina Uhlmann
    Institute of Medical Oncology, Inselspital, University of Bern, Bern, Switzerland
    Oncology 67:117-22. 2004
    ..To determine the maximum tolerated dose (MTD), toxicity and activity of combined weekly paclitaxel and capecitabine in patients with metastatic breast cancer...
  31. ncbi request reprint Oxaliplatin: bimonthly, biweekly, or semimonthly?
    Bernhard C Pestalozzi
    J Clin Oncol 20:2758. 2002
  32. ncbi request reprint Gemcitabine-related pulmonary toxicity
    M Joerger
    Department of Internal Medicine, Division of Oncology, University Hospital, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Swiss Med Wkly 132:17-20. 2002
    ..Due to early diagnosis, prompt discontinuation of the drug, and treatment with steroids, toxicity was reversible in all cases...